PT  - JOURNAL ARTICLE
AU  - Daniele Barbaro
AU  - Paola Lapi
AU  - Paolo Viacava
AU  - Liborio Torregrossa
TI  - Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
AID  - 10.1136/bcr-2020-236934
DP  - 2020 Dec 01
TA  - BMJ Case Reports
PG  - e236934
VI  - 13
IP  - 12
4099  - http://casereports.bmj.com/content/13/12/e236934.short
4100  - http://casereports.bmj.com/content/13/12/e236934.full
SO  - BMJ Case Reports2020 Dec 01; 13
AB  - We report two cases of anaplastic thyroid cancer (ATC) which had a very good response to a treatment with lenvatinib at 14 mg. A 73-year-old man with ATC stage IVB was operated on, undergoing a near-total thyroidectomy, and the pathological remnant tissue showed a quick and partial response to treatment with the drug. The patient had a single metastasis in the brain after 9 months, but then died due to bronchopneumonia after undergoing a neurosurgical intervention for the complete removal of the lesion. A 74-year-old woman with ATC stage IV was operated on, undergoing a near-total thyroidectomy after a neoadjuvant treatment with the drug, that was continued after surgical treatment. She had a partial remission of the local disease and of distant metastasis, which lasted for 14 months. She then died 4 months later due to cancer progression. Lenvatinib at 14 mg appears to be effective, fast and well tolerated.